Evidence map›Paper›PMID 24604065›Full record

ArticleScientific reports2014

Targeting extracellular DNA to deliver IGF-1 to the injured heart.

Raffay S Khan, Mario D Martinez, Jay C Sy, Karl D Pendergrass, Pao-lin Che, Milton E Brown, E Bernadette Cabigas, Madhuri Dasari, Niren Murthy, Michael E Davis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Insulin-like growth factor-1 directly affects cardiac cellular remodellingInternational journal of cardiology. Heart & vasculature · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. NovelACS medicinal chemistry letters · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Raffay S KhanDivision of Cardiology, Emory University, Atlanta, Georgia 30322, USA.
Mario D MartinezWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA.
Jay C SyWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA.
Karl D PendergrassDivision of Cardiology, Emory University, Atlanta, Georgia 30322, USA.
Pao-lin CheWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA.
Milton E Brown1] Division of Cardiology, Emory University, Atlanta, Georgia 30322, USA [2] Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA.
E Bernadette CabigasWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA.
Madhuri DasariWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA.
Niren Murthy1] Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA [2] Department of Bioengineering, University of California at Berkeley, Berkeley, CA, 94720, USA.
Michael E Davis1] Division of Cardiology, Emory University, Atlanta, Georgia 30322, USA [2] Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA [3] Department of Bioengineering, University of California at Berkeley, Berkeley, CA, 94720, USA [4] Emory+Children's Center for Cardiovascular Biology, Children's Healthcare of Atlanta, Atlanta, GA 30332, USA.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
NHLBI NIH HHS HHSN268201000043CNIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

There is a great need for the development of therapeutic strategies that can target biomolecules to damaged myocardium. Necrosis of myocardium during a myocardial infarction (MI) is characterized by extracellular release of DNA, which can serve as a potential target for ischemic tissue. Hoechst, a histological stain that binds to double-stranded DNA can be conjugated to a variety of molecules. Insulin-like growth factor-1 (IGF-1), a small protein/polypeptide with a short circulating-half life is cardioprotective following MI but its clinical use is limited by poor delivery, as intra-myocardial injections have poor retention and chronic systemic presence has adverse side effects. Here, we present a novel delivery vehicle for IGF-1, via its conjugation to Hoechst for targeting infarcted tissue. Using a mouse model of ischemia-reperfusion, we demonstrate that intravenous delivery of Hoechst-IGF-1 results in activation of Akt, a downstream target of IGF-1 and protects from cardiac fibrosis and dysfunction following MI.

Indexed as

AnimalsCell LineDisease Models, AnimalDNAExtracellular SpaceFibrosisHumansInsulin-Like Growth Factor IMacrophagesMaleMiceMyocardial InfarctionMyocardial Reperfusion InjuryMyocytes, CardiacProtein BindingProtein TransportDNAInsulin-Like Growth Factor I

Identifiers

PMID24604065
PMCPMC3945489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.